Understanding the Metabolic Impact of Aldehyde Oxidase on New Drug Design

描述（由申请方提供）：本提案旨在开发醛氧化酶（AOX）结合亲和力（目标1）和体内人体清除率（目标2）的计算机模拟模型。最近有三种化合物在临床试验中失败，原因是在进入人体之前缺乏AOX代谢的知识。其中一种化合物导致受试者的肾毒性。这些失败是任何临床前物种无法预测AOX代谢的结果。此外，据报道，人胞质溶胶也不能准确预测体内人清除率。初步结果支持我们的努力，准确地预测人体清除率使用计算机方法。我们能够以合理的准确度（r2 = 0.8）预测8种已施用于人体的化合物的人体清除率。我们还提供了8个化合物的AOX抑制的初步结果。除一种化合物外，所有这些化合物均显示复杂的抑制动力学。从抑制结果，我们能够确定，两种化合物，氯氮平和氯丙嗪，有足够高的亲和力，显示药物相互作用。在目标1中，我们将使用来自100个AOX抑制剂的数据开发定量结构抑制关系（QSIR）。这些QSIR模型将有多种用途，其中之一将是预测潜在的药物相互作用。在目标2中，我们将改进AOX清除的模型。同样，这些模型将有多种用途，并提供了这些酶如何在药物代谢中工作的强有力的理解。我们假设目标1和目标2的模型可以用于药物开发，以帮助消除药物失败。

DESCRIPTION (provided by applicant): This proposal aims to develop in silico models for aldehyde oxidase (AOX) binding affinities (Aim 1), and in vivo human clearance (Aim 2). Three compounds have failed recently in clinical trials as a result of the lack of knowledge of AOX metabolism prior to entering humans. One of these compounds led to kidney toxicity in the test subjects. These failures are a result of the inability of any preclinical species to predict AOX metabolism. Furthermore, it has been reported that human cytosol can also fail to accurately predict in vivo human clearance. Preliminary results support our efforts to accurately predict human clearance using in silico methods. We were able to predict human clearance with a reasonable amount of accuracy (r2 = 0.8) for 8 compounds that have been administered to humans. We also provide preliminary results for the inhibition of AOX for 8 compounds. All but one of these compounds show complex inhibition kinetics. From the inhibition results, we are able to determine that two compounds, clozapine and chlorpromazine, have high enough affinities to show drug-drug interactions. In Aim 1, we will develop quantitative structure inhibition relationships (QSIR) using data from 100 inhibitors of AOX. These QSIR models will have multiple uses, one of which will be predicting potential drug-drug interactions. In Aim 2, we will refine our models for AOX clearance. Again, these models will have multiple uses, and provide a strong understanding of how these enzymes work in drug metabolism. We hypothesize that the models from Aim 1 and Aim 2 can be used in drug development to help eliminate drug failures.